Cronobacter sakazakii
Powdered infant formula isn’t sterile — and Cronobacter sakazakii is the reason preparation instructions are so exact. In neonates it causes meningitis and necrotizing enterocolitis with appalling fatality rates. Rare, devastating, and entirely about manufacturing and preparation discipline.
Taxonomy & characteristics
- Cronobacter sakazakii (formerly Enterobacter sakazakii; family Enterobacteriaceae); Gram-negative rod.
- Notably desiccation-resistant — survives in dry powder for extended periods; also relatively heat-tolerant for a non-spore-former.
- Growth limits (approx): temperature ~6–45°C; can grow in reconstituted formula left at room temperature.
- Disease: neonatal/infant meningitis, bacteremia, necrotizing enterocolitis — low incidence, very high severity in premature and low-birth-weight infants.
Sources & high-risk foods
- Reservoir: the manufacturing environment — dry processing areas, where it persists; also household environments.
- High-risk: powdered infant formula (and follow-on formula); reconstituted formula held warm.
Control measures
- Manufacturing: dry hygienic design, environmental monitoring for Enterobacteriaceae/Cronobacter, validated kill steps in wet-mix processes.
- Preparation (WHO guidance): reconstitute with water ≥70°C, cool quickly, use within 2 hours or refrigerate; discard unfinished feeds.
- Hospitals: heightened vigilance for neonatal units; ready-to-feed sterile formula for the highest-risk infants.
The 2022 US infant formula shortage — triggered by a plant shutdown following Cronobacter illnesses — showed how a single facility’s contamination can cascade through a concentrated market. The crisis reshaped FDA’s approach: increased inspections of formula plants, new attention to Cronobacter as more than a sporadic hazard, and supply-chain resilience questions Congress is still asking. For manufacturers, the lesson is that powdered infant formula’s risk profile demands environmental monitoring and hygienic zoning at pharmaceutical-adjacent levels — the product’s consumers have no immune margin, and the market has no supply margin either.
Sources: FDA; WHO/FAO; EFSA.